These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 21654612)
1. Selective estrogen receptor modulators: the future in menopausal treatment. Palacios S Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612 [TBL] [Abstract][Full Text] [Related]
2. Use of SERMs for treatment in postmenopausal women. Pinkerton JV; Thomas S J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794 [TBL] [Abstract][Full Text] [Related]
3. The future of the new selective estrogen receptor modulators. Palacios S Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265 [TBL] [Abstract][Full Text] [Related]
4. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Pickar JH; Mirkin S Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688 [TBL] [Abstract][Full Text] [Related]
5. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Maeda T; Ke HZ; Simmons H; Thompson D Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137 [TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Gennari L Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205 [TBL] [Abstract][Full Text] [Related]
8. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV; Goldstein SR Menopause; 2010; 17(3):642-53. PubMed ID: 20107426 [TBL] [Abstract][Full Text] [Related]
13. Selective estrogen modulators in menopause. Gambacciani M Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250 [TBL] [Abstract][Full Text] [Related]
14. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Archer DF Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718 [No Abstract] [Full Text] [Related]
15. [Bazedoxifene as a new-generation SERM]. Ohta H Clin Calcium; 2011 Jan; 21(1):34-42. PubMed ID: 21187592 [TBL] [Abstract][Full Text] [Related]
16. The evolution of selective estrogen receptor modulators in osteoporosis therapy. Hadji P Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318 [TBL] [Abstract][Full Text] [Related]
17. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Gennari L Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439 [TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Gennari L; Merlotti D; Nuti R Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039 [TBL] [Abstract][Full Text] [Related]
19. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD Menopause; 2006; 13(4):609-20. PubMed ID: 16837883 [TBL] [Abstract][Full Text] [Related]
20. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Peano BJ; Crabtree JS; Komm BS; Winneker RC; Harris HA Endocrinology; 2009 Apr; 150(4):1897-903. PubMed ID: 19022889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]